11.95
-0.36(-2.92%)
Currency In USD
| Previous Close | 12.31 |
| Open | 12.2 |
| Day High | 12.5 |
| Day Low | 11.9 |
| 52-Week High | 18.51 |
| 52-Week Low | 7.55 |
| Volume | 886,481 |
| Average Volume | 1.36M |
| Market Cap | 1.16B |
| PE | -23.9 |
| EPS | -0.5 |
| Moving Average 50 Days | 11.87 |
| Moving Average 200 Days | 12.18 |
| Change | -0.36 |
If you invested $1000 in ARS Pharmaceuticals, Inc. (SPRY) since IPO date, it would be worth $478 as of March 14, 2025 at a share price of $11.95. Whereas If you bought $1000 worth of ARS Pharmaceuticals, Inc. (SPRY) shares 3 years ago, it would be worth $3,319.44 as of March 14, 2025 at a share price of $11.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
GlobeNewswire Inc.
Mar 05, 2025 9:10 PM GMT
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk pat
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
GlobeNewswire Inc.
Mar 03, 2025 9:35 PM GMT
Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protec
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
GlobeNewswire Inc.
Feb 21, 2025 12:02 AM GMT
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary platforms cover